Interaction effect between COXi use and pretreatment NLR or type of ICI
| ICI+COXi versus ICI alone | ||
| Melanoma cohort | Modified melanoma cohort | |
| HR (95% CI) | HR (95% CI) | |
| Pretreatment NLR | ||
| High (NLR>5) | 0.08 (0.03 to 0.25) | 0.06 (0.02 to 0.24) |
| Low (NLR≤5) | 0.65 (0.32 to 1.32) | 0.7 (0.3 to 1.62) |
| Type of ICI | ||
| αPD-(L)1 | 0.62 (0.3 to 1.26) | 0.6 (0.27 to 1.34) |
| αCTLA-4 | 0.33 (0.13 to 0.82) | 0.21 (0.06 to 0.79) |
| αCTLA-4+αPD-1 | 0.47 (0.13 to 1.77) | 0.55 (0.14 to 2.14) |
COXi, cyclo-oxygenase inhibitors; αCTLA-4, cytotoxic T-lymphocyte-associated protein 4 antibody; ICI, immune checkpoint inhibitor; NLR, neutrophil-to-lymphocyte ratio; αPD-(L)1, programmed cell death protein (ligand) 1 antibody.